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Anticancer drugs generally have intracellular targets, implicating transport over the plasma membrane. For amphiphilic agents, such as
the anthracycline doxorubicin, this occurs by passive diffusion. We investigated whether exogenous membrane-permeable lipid
analogues improve this drug influx. Combinations of drugs and lipid analogues were coadministered to cultured endothelial cells and
various tumour cell lines, and subsequent drug accumulation in cells was quantified. We identified N-hexanoyl-sphingomyelin (SM) as
a potent enhancer of drug uptake. Low micromolar amounts of this short-chain sphingolipid, being not toxic itself, enhanced the
uptake of doxorubicin up to 300% and decreased its EC50 toxicity values seven- to 14-fold. N-hexanoyl SM acts at the level of the
plasma membrane, but was found not incorporated in (isolated) lipid rafts, and artificial disruption or elimination of raft constituents
did not affect its drug uptake-enhancing effect. Further, any mechanistic role of the endocytic machinery, membrane leakage or ABC-
transporter-mediated efflux could be excluded. Finally, a correlation was established between the degree of drug lipophilicity, as
defined by partitioning in a two-phase octanol–water system, and the susceptibility of the drug towards the uptake-enhancing effect
of the sphingolipid. A clear optimum was found for amphiphilic drugs, such as doxorubicin, epirubicin and topotecan, indicating that
N-hexanoyl-SM might act by modulating the average degree of plasma membrane lipophilicity, in turn facilitating transbilayer drug
diffusion. The concept of short-chain sphingolipids as amphiphilic drug potentiators provides novel opportunities for improving drug
delivery technologies.
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Insufficient delivery of chemotherapeutic agents to their intended
molecular targets remains a major obstacle in clinical oncology.
Most anticancer drugs act intracellularly, which involves a
transport step over the plasma membrane. The maximally reached
intracellular drug concentration largely determines the efficacy of
these compounds (Speth et al, 1988). Optimisation of influx, across
the plasma membrane barrier of target cells, would therefore
increase the therapeutic efficacy of a drug. Hydrophilic com-
pounds are presumed to traverse the plasma membrane by
relatively slow processes, such as carrier-mediated transport or
endocytic uptake. More efficient in this respect are lipophilic
drugs, which readily cross the lipid bilayer by passive diffusion,
along their concentration gradient (Robert and Gianni, 1993;
Washington et al, 2001). However, given the fact that anticancer
drugs are generally applied systemically, maintenance of plasma
solubility is an additional specification for these compounds.
Vacillating between these opposite requirements, antineoplastic
agents often exhibit an amphiphilic nature. Optimisation of
cellular drug uptake is traditionally sought for by modification
of lipophilicity. However, this often compromises interactions with
its molecular target (Weiss, 1992).
The amphiphilic anthracycline doxorubicin is probably the best-
studied example in drug–membrane interactions. Adsorption,
insertion and flip-flop can be distinguished as consecutive stages
in the transport of this compound across membranes (Regev and
Eytan, 1997; Lecompte et al, 2002). Studies performed with model
systems, such as large unilamellar vesicles, E. coli mutants and
erythrocytes, revealed that membrane potential, pH and electro-
static forces play important roles in this (Terasaki et al, 1984;
Nishiyama et al, 1992; de Wolf et al, 1993; Speelmans et al, 1997).
Furthermore, hydrophobic interactions, membrane fluidity and
drug lipophilicity are decisive for efficient drug import (Jedrzejc-
zak et al, 1999; Schuldes et al, 2001). In line with these
observations, it is of interest that the lipid composition of model
membranes determines the efficiency of anthracycline transloca-
tion, and it is well conceivable that this also holds for natural
membranes (Speelmans et al, 1994; Lecompte et al, 2002).
Plasma membrane lipid bilayers are composed of dozens of
different lipid species, whose distribution is far from homogeneous
due to the presence of microdomains such as lipid rafts and
caveolae (Sprong et al, 2001; Simons and Ehehalt, 2002). The main
principle underlying microdomain formation is the auto-organis-
ing capacity of sphingolipids, such as sphingomyelin (SM) and
glycosphingolipids, both with themselves and in association with
cholesterol. Owing to their relative insolubility in nonionic
detergents, such as Triton X-100, these structures have been
biochemically (operationally) defined as the detergent-resistant
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smembrane fraction (DRM). The number of different types of
(micro)domains are unknown, but presumably the outer leaflet of
the plasma membrane should be considered as a mosaic-like
patchwork with a differentiated lipid distribution (Gruenberg,
2001). This model implies local differences in lipophilicity and
membrane fluidity, which in turn might determine the site and
efficiency of cellular drug entry.
Several tools are available for manipulation of the plasma
membrane lipid composition and distribution. Inhibitors of
endogenous lipid-metabolising enzymes and cholesterol-seques-
tering agents are generally used (Radin et al, 1993; Ohvo and
Slotte, 1996). Furthermore, (bacterial) lipid-metabolising enzymes
can be administered to cultured cells (Veldman et al, 1998). In
addition to these indirect approaches, lipids might also be added
directly to cells. Natural double-chain lipids, however, due to their
bulky hydrophobic nature, are poorly soluble and do not insert
spontaneously into cellular membranes. These natural (phospho)-
lipids, containing fatty acids composed of 16–24 carbon atoms, are
useful in liposomal drug delivery systems, but not as single
molecules. The use of truncated analogues, on the other hand,
improves both solubility and membrane permeability of the lipids.
Typically, such analogues contain one or two truncated chains,
consisting of only 2 (acetyl; C2), 6 (hexanoyl; C6) or 8 (octanoyl;
C8) carbon atoms, and easily insert as monomers in a lipid bilayer.
Being structurally closely related to their natural counterparts,
these semisynthetic analogues appear to be transported and
metabolised normally (Watanabe et al, 1999). Some lipid
analogues elicit strong cellular responses. C6-ceramide, for
example, rapidly induces apoptosis in a number of cell types
(Veldman et al, 1998). Others, such as C6-SM, appear to be rather
inert in this respect.
With the present in vitro work, we investigated whether
plasma membrane lipid manipulation is a feasible strategy for
increasing the cellular entry of doxorubicin and other amphiphilic
drugs. Of all tested methods, treatment of cells with C6-SM
exhibited the most prominent effect on cellular doxorubicin
uptake and cytotoxicity. Since the lipid itself was nontoxic at its
effective concentrations (low micromolar), C6-SM should be
considered as a novel potentiator of doxorubicin cytotoxicity.
While natural long-chain SM is a common constituent of
liposomal drug formulations, in which it serves a mere structural
role (Betz et al, 2001), the short-chain SM analogue acts directly in
the drug uptake process itself. Herewith, we provide the first
example of a synthetic lipid that acts as a delivery enhancer of a
pharmacon. As such, this finding holds promise for in vivo
applications.
MATERIALS AND METHODS
Materials
Bicinchoninic acid (BCA) protein kit, 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyl tetrazolium bromide (MTT), C6-ceramide (C6-Cer),
C8-ceramide-1-phosphate (C8-Cer-1P), sphingosylphosphorylcho-
line, dihexanoyl-phosphatidylcholine, methyl-b-cyclodextrin
(CDX), S. aureus sphingomyelinase (bSMase), polyoxyethylene
20 oleyl ether (Brij 98), sulphorhodamine 101, propidium iodide,
o-phtaldialdehyde, bisbenzimidine, camptothecin and daunorubi-
cin were purchased from Sigma (St Louis, MO, USA). N-acetyl-
sphingomyelin (C2-SM), N-hexanoyl-sphingomyelin (C6-SM)
and DL-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol
(PPMP) were from Matreya (State College, PA, USA). AlexaFluor
488 (AF488) conjugates of hydrazide, cholera toxin b subunit
(CTB) and transferrin were from Molecular Probes (Leiden, The
Netherlands). Vectashield mounting medium was from Vector
Laboratories (Burlingame CA, USA) and the CytoTox 96 lactate
dehydrogenase (LDH) activity assay kit was from Promega
(Madison WI, USA). LK6D silica TLC plates were from Whatman
(Maidstone, UK). Doxorubicin was obtained from Pharmachemie
(Haarlem, The Netherlands), epirubicin from Pharmacia & Upjohn
(Woerden, The Netherlands), idarubicin from Farmitalia (Milan,
Italy) and topotecan from SmithKline Beecham (Conshohocken
PA, USA). 1-Octanol was from Riedel-de Hae ¨n (Seelze, Germany).
Cell culture
The following cell types were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% (vv
 1) foetal calf serum:
primary bovine aortic endothelial cells (BAEC; passage 14–19),
kindly provided by Dr A Haimovitz-Friedman (Memorial Sloan-
Kettering Cancer Center, New York City NY, USA); MCF-7, KB and
A431 carcinoma cells, purchased from the American Type Culture
Collection (Manassas VA, USA); SV40 large-T antigen-immorta-
lised kidney fibroblasts from Mrp1/Mdr1a/Mdr1b triple knockout
mice and control renal fibroblasts (Wijnholds et al, 2000; kindly
provided by Dr AH Schinkel, The Netherlands Cancer Institute,
Amsterdam). Cells were subcultured weekly by trypsinisation and
maintained in a water-saturated atmosphere of 10% (BAEC) or 5%
(MCF-7, KB, A431 and fibroblasts) CO2 at 371C. All culture media
were supplemented with 100Uml
 1 penicillin, 100mgml
 1 strep-
tomycin and 4mML -glutamine.
Microscopy
For microscopic studies, BAEC were cultured to confluence on
0.5%. (wv
 1) gelatin-coated glass coverslips. Under serum-free
conditions, cells were then exposed to 50mM doxorubicin for the
indicated periods of time. After washing, cells were fixed in 4%
(wv
 1) paraformaldehyde in PBS for 10min and mounted in
Vectashield on glass slides. Cells were then examined with a Zeiss
Axiovert S100 inverted fluorescence microscope, employing a
mercury lamp in combination with a filter set consisting of a 450–
490nm band pass excitation filter, a 510nm beam splitter and a
520nm long-pass emission filter. All specimens were photo-
graphed through a  20 objective by a Zeiss AxioCam CCD camera
using an exposure time of 200ms.
Cellular drug accumulation
For intracellular doxorubicin measurements, cells were cultured in
flat-bottom 96-well plates. At confluence, cells were changed to a
serum-free medium and exposed to 50mM doxorubicin during
60min (unless indicated otherwise). After washing with ice-cold
PBS, cells were lysed in 1% (wv
 1) Triton X-100 in water. Native
fluorescence intensities were then measured by a Perkin-Elmer
Victor Wallac II fluorescence microplate reader, using lex 485nm
and lem 535nm filters. Additional probes and drugs that were
tested for cellular uptake during 60min incubations, either in the
absence or presence of lipid, were hydrazide-AF488 (35mM, lex
485nm, lem 535nm), sulphorodamine-101 (400mM, lex 355nm,
lem 620nm), propidium iodide (300mM, lex 355nm, lem 535nm),
o-phtaldialdehyde (1mM, lex 485nm, lem 535nm), topotecan
(30mM, lex 355nm, lem 535nm), epirubicin (50mM, lex 485nm, lem
535nm), bisbenzimidine (10mM, lex 355nm, lem 460nm), camp-
tothecin (30mM, lex 355nm, lem 460nm), daunorubicin (25mM, lex
485nm, lem 535nm) and idarubicin (20mM, lex 485nm, lem
535nm). All values were corrected for background fluorescence (or
radioactivity) and for differences in protein content, as determined
with the BCA assay (Smith et al, 1985).
Cell viability
For viability assessment, cells were cultured in flat-bottom
96-well plates. After experimental treatments, 100mg of the
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smitochondrial dehydrogenase substrate MTT was added to
each well (Carmichael et al, 1987). Cells were then incubated for
60min at 371C. After centrifugation (3000rpm, 10min) super-
natants were removed. The precipitated blue formazan products
were then dissolved in 100ml DMSO and absorbencies were read
in a Bio-Tek Instruments EL 340 photospectrometric microplate
reader at 540nm. Background absorbencies were subtracted
and values from untreated control cells were set at 100%
viability.
Plasma membrane integrity assessment
Confluent and serum-free BAEC were incubated for 120min
in the presence of C6-SM and 175mM of the membrane impermeant
fluid phase marker hydrazide-AF488. After washing, cells
were lysed in PBS containing 1% (wv
 1) Triton X-100 and
fluorescence was measured at lex 485nm and lem 535nm.
Alternatively, the release of the cytosolic enzyme LDH
from confluent BAEC into phenol red-free DMEM was measured.
For this, plates were centrifuged (5min, 2000rpm) and
50ml aliquots of the supernatants were assessed for LDH
activity by using the CytoTox 96 kit, according to the manufac-
turer’s instructions. Values obtained from cells lysed in 0.8%
Triton X-100 served as positive control. All data were corrected for
protein contents, as determined with the BCA assay (Smith et al,
1985).
Endocytosis assays
To monitor clathrin- and raft-mediated endocytic activity,
confluent BAEC were allowed to take up AF488-transferrin
(150mgml
 1) or AF488-CTB (75mgml
 1), respectively. Incuba-
tions were performed under serum-free conditions in the presence
of 10mM C6-SM during 120min. Cells were then washed and lysed
in PBS containing 1% (vv
 1) Triton X-100. Fluorescence was then
measured at lex 485nm and lem 535nm. Values were corrected for
protein content, as determined with the BCA assay (Smith et al,
1985).
Isolation of detergent-resistant membrane fraction
For each isolation, four confluent + 15cm dishes with
confluent BAEC were treated as indicated. Cells were then
washed twice with ice-cold PBS and harvested by scraping and
centrifugation (3000rpm, 5min, 41C). Pellets were resuspended
in 1ml of ice-cold 0.5% (wv
 1) Triton X-100 in MES-buffered
saline (MBS; 25mM 2-[N-morpholino]ethanesulphonic acid in
150mM NaCl, pH 6.5) (Lisanti et al, 1995). After 30min on ice,
1.2ml of MBS was added and 2ml of this suspension was mixed
with 2ml 80% sucrose (wv
 1) in MBS and transferred to Beckman
Ultraclear 14 89mm tubes. This layer was overlaid with cushions
of 5ml 30% (wv
 1) and 3ml 5% (wv
 1) sucrose in MBS,
respectively. Remnants of the initial suspension were used for the
determination of total protein, drug and lipid contents (designated
as total). Gradients were subjected to ultracentrifugation in an
SW41 swing-out rotor (39000rpm, 16h, 41C). After each run,
opaque bands of insoluble material were visible in the upper half of
each gradient. Tubes were aspirated in 1ml fractions, of which the
upper six (designated as DRM) and the lower six were pooled
(designated as non-DRM). Alternatively, the whole procedure was
carried out at room temperature using 1% (wv
 1) Brij 98 as
detergent (Pike et al, 2002).
Sphingomyelin quantification
Total lipids were extracted from the sucrose gradient fractions and
dried under a stream of N2 (Bligh and Dyer, 1959). Glycerol-
containing phospholipids were hydrolysed during an overnight
incubation at 371C in 0.2 M NaOH in methanol/chloroform (1:1,
by vol.). The remaining lipids were then re-extracted, dried
and applied onto TLC plates, which were developed at
room temperature using chloroform/methanol/water (60:30:8,
by vol.) as the mobile phase. Lipids were visualised by iodine
vapour staining and natural SM and C6-SM containing spots
were identified with the aid of external standards, run on the
same plate. Confirmation of this identification took place by
bSMase pretreatment (0.1Uml
 1, 2h, 201C) of C6-SM-loaded
cells before the extraction. Both SM and C6-SM spots were scraped
from the plate and subjected to a colorimetric phosphate
determination, using inorganic phosphate as standard (Bo ¨ttcher
et al, 1961).
Determination of lipophilicity
Partitioning of 10–50mM drug or probe was monitored in a two-
phase system consisting of 1ml 1-octanol and 1ml water. After
addition of the compound, tubes were vortexed and centrifuged
(3000rpm, 5min, 201C). Aliquots of both the organic and the
aqueous phases were taken for fluorimetric quantification, as
described under Cellular drug accumulation. As a measure of
lipophilicity, the 1-octanol/water partitioning ratio was calculated
for each compound and expressed on a log scale (Washington et al,
2001).
RESULTS
Cellular doxorubicin uptake and toxicity is specifically
enhanced by C6-SM
To study the cellular uptake of doxorubicin in vitro, BAEC were
exposed to 50mM of the drug, and intracellular accumulation was
then monitored, either by fluorescence microscopy or by
fluorimetry of cell lysates. Under control conditions, intracellular
doxorubicin accumulation proceeded in a time-dependent man-
ner, starting within minutes upon addition (Figure 1a–e and
Figure 2). This kinetic altered significantly when cells were
cotreated with 10mM of C6-SM (Figure 1f–j and Figure 2). Under
these conditions, intracellular doxorubicin was observed within
the first minute and increased up to 300% over control levels for
incubation periods of 15–60min (Figure 2, inset). This relative
increase gradually diminished when doxorubicin uptake was
monitored for longer periods.
The observed doxorubicin uptake-enhancing effect of C6-SM in
BAEC was clearly concentration-dependent (Figure 3a).
A significant increase in drug uptake was seen at lipid concentra-
tions as low as 2mM. However, a maximum increase of 300%
over control values was reached at 6mM of C6-SM. No further
increases were observed at higher concentrations. Comparable
results were obtained in a panel of human doxorubicin-sensitive
tumour cell lines: MCF-7 (mammary adenocarcinoma), KB
(oesophagal carcinoma) and A431 (epidermoid carcinoma) cells
(Figures 3b–d).
To test whether increased intracellular concentrations of
doxorubicin correlated with increased cytotoxicity, we allowed
BAEC and tumour cell lines to accumulate doxorubicin for 60min
in the presence of varying concentrations of C6-SM. After washing
away remaining extracellular drug and lipid, cells were cultured for
another 48h. Viability was then assessed by the MTT assay, which
relies on the fact that only mitochondria of viable cells have the
capacity to convert the MTT substrate (Carmichael et al, 1987). A
concentration series of doxorubicin resulted in typical sigmoid
survival curves for BAEC and A431 cells (Figures 4a and b). Curves
of cells that accumulated doxorubicin in the presence of C6-SM
shifted leftward, indicating increased cell death. The doxorubicin
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RJ Veldman et al
919
British Journal of Cancer (2004) 90(4), 917–925 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sEC50 value for BAEC toxicity shifted from 4mM in the absence of
C6-SM to 0.6mM for cells treated with 10mM of C6-SM, indicating a
seven-fold increase in sensitivity. In A431 cells, C6-SM shifted back
doxorubicin EC50 values from 1.8 to 0.13mM, thus yielding a 14-
fold increase in drug sensitivity. When plotted against the C6-SM
concentration, it is evident that essentially no further decreases in
doxorubicin EC50 occurred above 6mM of lipid (insets of Figures 4a
and b), and that low micromolar concentrations were relatively
most beneficial in this respect. Similar results were obtained with
MCF-7 and KB cells (not shown). C6-SM itself was virtually
nontoxic at the presently used concentrations and incubation
periods (not shown).
To examine which molecular features of C6-SM are critical for its
doxorubicin uptake-enhancing properties, we tested a series of
closely related (synthetic) lipid analogues (Table 1), in an assay
similar as employed for C6-SM. We established that short-chain
sphingolipid analogues without a choline or phosphocholine head
group moiety (C8-ceramide-1-phosphate and C6-ceramide, respec-
tively) had little or no effect. Sphingosylphosphorylcholine
(C0-SM) and C2-SM exhibited a moderate effect, whereas short-
chain phosphatidylcholine, a glycerol-containing lipid, was com-
pletely without effect. Thus, the observed effect on drug uptake is
optimal for phosphocholine-containing truncated sphingolipid
analogues, but the N-acyl truncation should not be too rigorous
and probably not too small either, since supplementation of
natural long-chain SM does not work.
C6-SM does not act by inducing membrane leakage,
endocytosis or efflux inhibition
Plasma membrane integrity was monitored by measuring the
uptake of the fluid phase marker hydrazide-AF488 by BAEC. No
additional inward flux of this membrane-impermeant marker was
observed in the presence of 10mM C6-SM (97.4718.2% uptake, as
compared to 100% control uptake). Conversely, no C6-SM-induced
release of the cytosolic enzyme LDH was observed (19.073.9% of
total LDH activity released into the culture medium within an hour
under control conditions, and 19.773.5% in the presence of 10mM
C6-SM). These data are consistent with each other, indicating that
C6-SM leaves the plasma membrane physically intact.
We investigated whether C6-SM stimulates the endocytic
machinery in our system by using fluorescent conjugates of
transferrin and the CTB subunit, as markers for clathrin- and raft-
mediated endocytosis, respectively (Mellman, 1996; Orlandi and
Fishman 1998). No increased uptake of fluorescence by BAEC in
the presence of the lipid was observed. Instead, a small decrease
was detectable (67736% of transferrin and 80723% of CTB
uptake, as compared to 100% uptake under control conditions).
Moreover, when cells were maintained at 41C or were depleted for
ATP (with sodium azide and deoxyglucose; Schwoebel et al, 2002),
conditions that block endocytosis, the C6-SM-stimulated doxor-
ubicin uptake remained unaffected. Thus, we conclude that the C6-
SM effect is unrelated to endocytosis.
Although the presently used cells express only modest levels of
drug transporter proteins, such as MDR1 and MRP1, we tested for
the possible involvement of these proteins in the observed C6-SM
effect on doxorubicin uptake. Three different experimental
approaches were employed (Table 2). (1) Since ABC-transporters
are energy-dependent, we used a regimen of sodium azide and
deoxyglucose that eventually depletes cells from ATP (Schwoebel
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Figure 1 C6-SM enhances the cellular uptake and nuclear accumulation
of doxorubicin. Confluent BAEC were incubated for the indicated periods
with 50mM of doxorubicin, either in the absence (A–E) or presence (F-J)
of 10mM C6-SM. Cells were then washed and fixated in 4% (vv
 1)
paraformaldehyde. After mounting, cells were examined by fluorescence
microscopy, employing a filter set consisting of a 450–490nm band pass
excitation filter, a 510nm beam splitter and a 520nm long pass emission
filter. All specimens were photographed through a  20 objective using a
200ms exposure time.
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Figure 2 Uptake-enhancing effect of C6-SM on doxorubicin is most
evident within the first hour. Confluent BAEC were incubated for the
indicated periods with 50mM of doxorubicin, either in the absence (J)o r
presence (K)o f1 0mM C6-SM. Cells were then washed and lysed by 1%
(wv
 1) Triton X-100 in PBS. Employing its native fluorescent properties,
doxorubicin was quantified fluorimetrically by comparison to standard
amounts of the drug in the same lysis buffer. Data are expressed as nmol
per mg of cellular protein (mean7s.d., n¼6) and plotted against time
(min) on a
2log scale. The inset shows the relative effect of C6-SM on
doxorubicin uptake, as compared to the control cells (%7s.d.).
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Figure 3 Concentration-dependency of the C6-SM effect on doxor-
ubicin accumulation. BAEC (A), MCF-7 (B), KB (C) and A431 (D) cells
were incubated with the indicated concentrations of C6-SM and 50mM
doxorubicin for 60min. After washing, cellular drug accumulation was
determined fluorimetrically and all data were corrected for protein
contents (n¼6). Data are expressed as percentage (7s.d.) to the cellular
doxorubicin accumulation under control conditions (50mM drug, no lipid).
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Figure 4 C6-SM potentiates the cytotoxic effect of doxorubicin at low
micromolar concentrations. BAEC (A) and A431 (B) cells were incubated
with various concentrations of doxorubicin, combined with 0mM (K), 2mM
(J), 4mM (’), 6mM (&), 8mM (m)o r1 0mM (n)C 6-SM. After 60min,
cells were washed and kept in culture for another 48h. Cell viability was
then assessed by the MTT assay. Data are expressed as mean percentages
(n¼3) to untreated control cells (no drug, no lipid; set at 100% viability).
The insets show the doxorubicin EC50 values of the viability curves plotted
against the administered C6-SM concentrations.
Table 1 Doxorubicin uptake-enhancing effect is an exclusive property of
truncated, phosphocholine-containing sphingolipids
Lipid (10lM)
Doxorubicin
(% of control7s.d.)
Control (no lipid, no ethanol) 100.0717.0
C6-sphingomyelin 328.3724.4
C8-ceramide 1-phosphate 116.5720.6
C6-ceramide 105.676.5
Sphingosinephosphorylcholine 143.2710.0
C2-sphingomyelin 129.6719.6
C6-phosphatidylcholine 101.0728.2
Vehicle control (1% vv
 1 ethanol) 91.574.8
A measure of 10mM of the indicated lipid analogue was administered to BAEC in
combination with 50mM of doxorubicin. After 60min, cellular drug content was
determined fluorimetrically after washing and lysis in 1% (vv
 1) TX-100. All values
were corrected for protein contents and data are expressed as mean percentage to
control (no lipid, no ethanol) (7s.d., n¼3). C6-SM had little effect on the fluorescent
properties of doxorubicin and hence its quantification (50mM of doxorubicin yielded
fluorescence levels of 939067793 in the presence of 10mM C6-SM vs 8601971060
in the absence of the lipid). Furthermore, C6-SM did not induce any interaction
between doxorubicin and plastic cell culture ware (only 6.274.4% of additional
residual plastic-associated doxorubicin in the presence of 10mM C6-SM).
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set al, 2002). Under these conditions, and in the absence of
C6-SM, no accumulation of doxorubicin in BAEC was detected
above control levels. In addition, no significant increase in the
C6-SM effect was observed. (2) PSC833 and MK571 are inhibitors
of MDR1 and MRP1, respectively (Mayer et al, 1997; Kok et al,
2000). At their effective concentrations, no additional accumula-
tion of doxorubicin was observed in the absence of C6-SM, and
no further increase was observed in the presence of C6-SM,
not even in combination with ATP depletion (not shown). (3) Like
in normal fibroblasts, the doxorubicin uptake-enhancing effect
of C6-SM was observed in fibroblasts that we derived from
Mrp1/Mdr1a/Mdr1b triple knockout mice (a three- to four-fold
increase, as compared to doxorubicin uptake in the absence of the
lipid analogue) (Wijnholds et al, 2000). Collectively, the data
obtained from these metabolic, pharmacological and genetic
approaches (Table 2) allow us to conclude that the C6-SM effect
on doxorubicin accumulation is unrelated to ABC-transporter
proteins.
C6-SM inserts into the plasma membrane but its effect is
independent of lipid rafts
Within 60min, only an estimated 1.5% of the total added amount
of C6-SM (at 10mM) was taken up by BAEC, reflecting the relative
water-solubility of the truncated lipid. When compared to the
cellular pool of endogenous SM (13.1573.96nmolmg
 1 of
protein), this fraction of inserted C6-SM was nevertheless
substantial (1.8170.47nmolmg protein
 1). This cell-associated
C6-SM was fully responsible for the enhanced doxorubicin uptake,
since the effect remained after washing away C6-SM that had not
been taken up by the cells. The drug uptake-enhancing effect was
strongly diminished when membrane-inserted C6-SM was hydro-
lysed by exogenously applied bSMase, or by extraction by a BSA
back-exchange procedure (not shown). Since bSMase and BSA act
from outside at the cell surface and have no access to the cell
interior, these results indicate that C6-SM exerts its effect in the
outer leaflet of the plasma membrane lipid bilayer.
Given the fact that natural long-chain SM is highly enriched in
lipid rafts, we questioned whether C6-SM would likewise
accumulate into these lipid microdomains. To answer this
question, we employed an established isolation procedure, based
on the insolubility of these membrane microdomains in ice-cold
Triton X-100, combined with ultracentrifugation on a discontin-
uous sucrose gradient (Lisanti et al, 1995). As expected, natural SM
was highly enriched in this DRM fraction (Table 3). C6-SM, on the
other hand, was predominantly present in the non-DRM. The
distribution of endogenous SM in control cells was identical to that
of C6-SM-treated cells, indicating that no jostling of natural SM
occurred by its truncated counterpart. To exclude the possibility
that low temperatures and the use of a detergent like Triton X-100
induced artefactual changes in the distribution of (short-chain)
lipids, we repeated the experiment with Brij 98, allowing raft
isolation at room temperature (Pike et al, 2002). However, the
distribution of both natural and short-chain SM over the DRM vs
non-DRM fractions was identical to those of the Triton X-100
isolation (not shown).
We investigated whether the doxorubicin uptake-enhancing
effect of the lipid might nevertheless be functionally dependent on
lipid rafts. We therefore, in BAEC, strongly reduced the levels of
cholesterol, SM and glycosphingolipids, the major lipid constitu-
ents of rafts, by employing CDX, bSMase and PPMP, respectively
(Radin et al, 1993; Ohvo and Slotte, 1996; Veldman et al, 1998).
Although each of these compounds exhibits a strong impact on the
integrity and function of lipid rafts, none of these induced effects
on doxorubicin uptake itself, nor on the C6-SM-enhancing effect
on this (Table 4).
C6-SM acts optimally on amphiphilic compounds
In addition to doxorubicin, we tested an array of fluorescent
chemotherapeutic drugs and intracellular probes for their
Table 2 ABC-transporter proteins are not involved in C6-SM-enhanced doxorubicin uptake
Cell type C6-SM 10lM ATP depletion PSC833 5lM MK571 12.5lM Mrp1
 /  Mdr1a
 /  Mdr1b
/ 
Doxorubicin
(% of control7s.d.)
BAEC        100.0728.5
+       369.07113.0
  +      108.2746.7
++     410.97157.0
  +    76.0715.6
+   +    278.1740.7
   +   103.5730.2
+   +   323.3723.0
Kidney fibroblasts        100.074.4
+       331.8750.2
     + 101.7714.3
+     + 385.1724.7
Doxorubicin accumulation was monitored in the indicated cell types during 60min, in the absence or presence of 10mM C6-SM. Cells were ATP-depleted during a 90min
preincubation in glucose-free culture medium, supplemented with 10mM 2-deoxy-D-glucose and 10mM sodium azide. Alternatively, 5mM PSC833 or 12.5mM MK571 was
administered to the cells at least 15min before exposure to doxorubicin. Kidney fibroblasts were isolated from control mice or from Mrp1/Mdr1a/Mdr1b triple knockout mice.
All data are expressed as mean percentages7s.d. (n¼3) to the untreated controls of either BAEC or fibroblasts.
Table 3 No preferential insertion of C6-SM into lipid rafts
Lipid Total DRM non-DRM
Endogenous SM 13.1573.96 11.8671.26 2.8770.34
Inserted C6-SM 1.8170.47 0.2270.17 1.1670.56
BAEC were incubated for 60min with 10mM C6-SM. DRM were then isolated by
solubilisation of the cells in ice-cold Triton X-100, and a subsequent ultracentrifuge
run on a discontinuous sucrose gradient (see Materials and Methods). The initial
Triton X-100 suspension was designated as total. The upper half of the gradient was
designated as DRM, and the lower half as non-DRM. Total lipids were extracted from
all three samples and glycerol-containing lipids were removed by a mild alkaline
hydrolysis procedure. The remaining lipids were then separated by TLC and visualised
by iodine vapour staining. C6-SM and endogenous SM containing spots were scraped
from the plate and subjected to a colorimetric phosphate determination. Lipid
contents are expressed as nmolmg
 1 of total cellular protein (7s.d., n¼3).
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ssensitivity towards C6-SM-uptake enhancement. In addition, we
determined the lipophilicity of each of these compounds by
establishing their partitioning ratio (P) over a defined 1-octanol/
water system (Washington et al, 2001). When these parameters
were plotted against each other (Figure 5), a clear optimum was
observed in the P range of 1–6 (amphiphilic to slightly lipophilic).
In addition to doxorubicin, other amphiphilic drugs such as
epirubicin and topotecan were identified as being C6-SM sensitive
as well. In contrast, both water-soluble compounds and very
lipophilic drugs such as camptothecin, daunorubicin and idar-
ubicin were mostly insensitive to C6-SM.
DISCUSSION
We discovered here that the short-chain sphingolipid analogue
C6-SM facilitates the cellular influx of amphiphilic drugs in vitro,
in turn leading to an enhanced cytotoxicity. This effect was
most pronounced for doxorubicin. This anthracycline showed
optimal lipophilicity, which turned out to be a decisive factor in
the C6-SM-facilitated uptake. The lipophilicity of chemically
related anthracyclines daunorubicin and idarubicin is significantly
higher, which correlated with less effect. The drug uptake-
enhancing effect turned out to be highly specific for C6-SM, since
even minor modifications in this sphingolipid structure largely
diminished the effect on drug uptake. At its active concentrations
(2–6mM), C6-SM itself was virtually nontoxic to cells. Therefore,
this lipid can be considered as a novel potentiator of doxorubicin
cytotoxicity.
The precise mechanism by which C6-SM enhances drug
uptake remains unestablished, but we ruled out the following
five possibilities: (1) C6-SM did not induce nonspecific membrane
damage, for example by exhibiting detergent-like effects. By (local)
dissolving of the plasma membrane, this would have resulted in an
increased drug influx. However, at the concentrations used in
this study, C6-SM did not increase the membrane permeability
of a hydrophilic marker molecule (AF488-hydrazide) or a cytosolic
protein (LDH), indicating that plasma membrane integrity
was indeed maintained. (2) The enhanced doxorubicin uptake
by C6-SM was not due to an increase in endocytic activity.
Although doxorubicin is known to traverse the plasma membrane
barrier by passive diffusion along its concentration gradient, it is
conceivable that some internalisation may also occur along with
(constitutive) endocytosis, and that C6-SM might stimulate this
route. In S. cerevisiae, for example, certain sphingolipids are
involved in endocytotic signalling processes (Friant et al, 2001).
However, C6-SM did not stimulate the cellular uptake of
transferrin and CTB, markers for, respectively, clathrin-dependent
and clathrin-independent endocytic routes. In addition, C6-SM-
enhanced doxorubicin uptake also occurred at low temperatures
and was ATP-independent. Together, these results exclude any
involvement of endocytic processes. (3) The effect of C6-SM did
not result from an interaction with members of the ATP-binding
cassette super family of transporter proteins (ABC transporter
proteins), which are able to mediate the efflux of anthracyclines
like doxorubicin against a concentration gradient (Borst and
Oude Elferink 2002). Some ABC transporter proteins, such as
MDR1 and MRP1, have the capacity to translocate lipids (Smit et al,
1993; van Helvoort et al, 1996; Schmitz et al, 2000).
Since intracellular drug concentrations are determined by a
balance between drug influx and efflux, C6-SM might have
indirectly caused a doxorubicin accumulation by inhibition of
the cellular efflux capacity. However, neither metabolic, nor
pharmacological, nor genetic intervention with the function of
ABC transporter proteins affected the C6-SM-enhanced doxorubi-
cin uptake. (4) No modification of doxorubicin by C6-SM occurs
before membrane insertion. The uptake-enhancing effect was
retained when the lipid and drug were presented to cells after each
other, with extensive washing in between. This observation
indicates that no complex formation between the two occurred
prior to plasma membrane association. Therefore, no possible
lipid-induced changes in the physicochemical properties of
doxorubicin can explain its increased uptake efficiency. (5)
Natural lipid rafts play no role in the C6-SM-enhanced drug
uptake. While natural long-chain SM is highly enriched in lipid
rafts (Veldman et al, 2001), its short-chain analogue, C6-SM, did
not accumulate in these membrane microdomains (at least not in
the DRM fraction). Furthermore, artificial disruption of these
microdomains, by either cholesterol extraction, SM hydrolysis or
glycosphingolipid depletion, had no effect on the doxorubicin
uptake-enhancing effect of C6-SM.
Table 4 C6-SM effect on doxorubicin uptake by BAEC is independent of
natural sphingomyelin and other lipid raft components
C6-SM
10lM
CDX 10mM,
30min
bSMase
200mUml
 1,
2h
PPMP
30lM,
96h
Doxorubicin (% of
control7s.d.)
       100.0713.4
+      353.3762.6
  +    113.0728.1
++    264.7772.1
   +   104.3714.2
+   +   386.2774.7
     + 166.5722.5
+    + 340.7778.6
Cells were pretreated by 10mM CDX for 30min, 200mUml
 1 bSMase for 2h or
30mM PPMP for 96h. The doxorubicin uptake-enhancing effect of C6-SM was then
established. Data are expressed as percentage (7s.d., n¼3) to control (no
pretreatment, no lipid).
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Figure 5 C6-SM uptake enhancement is optimal for amphiphilic
compounds. During a 60min period, confluent BAEC were allowed to
take up one of a series of fluorescent compounds, either in the absence
(control) or presence of 10mM C6-SM. After washing, drug accumulation
was determined by fluorimetric analysis of the cell lysates. The C6-SM effect
on cellular accumulation of the compounds is expressed as percentage to
the controls (mean7s.d., n¼4). These data are plotted against the (log)
lipophilicity of each compound, as determined by its partition ratio over a
two-phase system consisting of 1-octanol and water (mean7s.d., n¼4).
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sHaving excluded the above possibilities, what other clues do
we have to explain the lipid-enhanced drug uptake? Firstly, the C6-
SM effect is abrogated when the lipid is removed by BSA back-
extraction (simple washing with buffer is ineffective) or hydrolysed
by treatment with an exogenous bacterial SMase. Since BSA and
bSMase have no direct access to the cell interior, these results
indicate that C6-SM acts at the outer leaflet of the plasma
membrane. Furthermore, only a small fraction (1.5%) of the
supplied C6-SM is taken up by cells. This finding is consistent both
with its relative hydrophilicity and with the observed plateau in
doxorubicin-uptake enhancement and cytotoxicity, reached at
about 8mM of C6-SM (Figures 3 and 4). This possibly indicates a
saturation of particular membrane insertion sites. Once in the
membrane, C6-SM might not be randomly dispersed but, like
natural long-chain sphingolipids, show a tendency to self-
aggregate in the plane of the membrane (van Blitterswijk et al,
1987, 2003; Holopainen et al, 1998). It is therefore appealing to
speculate that these physical properties allow C6-SM to form their
own ‘artificial’ rafts, which, however, remain detergent soluble (as
found here). In this way, and by virtue of its acyl truncation, it may
be speculated that C6-SM induces local ‘voids’ in the lipid bilayer
that could accommodate doxorubicin molecules. Owing to the
resulting local changes in lipophilicity, thickness and fluidity, the
plasma membrane permeability for amphiphilic drugs would then
specifically be facilitated. Alternatively, self-aggregation of C6-SM
might lead to artificial ‘channels’ in the membrane, providing a
preferential gateway for drug uptake, similar as described, for
example for ceramides (Siskind and Colombini, 2000; Siskind et al,
2002). Unfortunately, the possible formation of distinct C6-SM
rafts or channels is difficult to prove experimentally at present.
Natural lipid rafts can be isolated as a DRM fraction, but C6-SM is
excluded from this fraction. Further investigation of this issue
therefore awaits the development of more sophisticated (deter-
gent-free) isolation procedures.
Since the present in vitro findings seem promising, it is
of interest to speculate on possible in vivo applications.
Of all drugs tested so far, doxorubicin turned out to be the
most sensitive towards the uptake-enhancing properties of C6-SM.
We used doxorubicin at a concentration of 50mM, which
corresponds well to common plasma concentrations in patients
upon a single bolus administration of 40–60mgm
 2 body surface.
The doxorubicin uptake-enhancing effect of C6-SM was particu-
larly strong within 15–60min of drug administration. Since the t1/2
clearance of systemically applied doxorubicin is approximately
1.25h, this is a very relevant interval, which would allow target
tissues to accumulate larger amounts of the drug (Robert and
Gianni, 1993). Theoretically, significant lower doses of doxorubicin
would thus be required to obtain a successful (clinical) outcome,
when coadministered with the short-chain sphingolipid. However,
to actually improve the therapeutic efficacy of doxorubicin by
coadministration of C6-SM, some advantageous (tumour) tissue
selectivity of the lipid is required. In this context, promising
preliminary results were obtained with cultured rat cardiac
myoblasts. For as yet unknown reasons, these cells are not
susceptible towards the sphingolipid analogues (Veldman et al,
unpublished observation). Given the fact that cardiotoxicity is an
important limiting factor in anthracycline-based chemotherapy,
this result is encouraging.
On the other hand, some open questions remain with respect to
the usefulness of systemically applied short-chain SM. Namely, due
to its affinity for serum components, such as albumin and
lipoproteins, or due to association with nonrelevant cell mem-
branes (e.g. erythrocytes), large amounts of the lipid might be
needed to reach the required plasma concentrations. Potential
hazards then include unwanted toxicity for vessel walls or other
nontumour tissues/cells. Furthermore, the possibility exists that C6-
SM and doxorubicin (or any other amphiphilic drug) differ in
pharmacokinetics, biodistribution and metabolism, and may thus
not be delivered at the same time at the same site, which is a
prerequisite for the drug uptake-enhancing effect. Extensive
pharmacological studies into the toxicity, efficacy, pharmacoki-
netics and bioavailability of C6-SM (in combination with amphi-
philic drugs or not) are therefore required to assess the feasibility of
clinical C6-SM-based drug delivery. Hopefully, our present in vitro
data will encourage new experiments in this direction.
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